[
  {
    "ts": "2026-01-21T14:03:00+00:00",
    "headline": "DATAMYTE RELEASES QPS PRO TO MEET AUTOMOTIVE OEM'S INCREASING DIGITAL QUALITY REQUIREMENTS",
    "summary": "ASI DATAMYTE, Inc. (\"DATAMYTE\"), a leading digital transformation and quality management provider to global manufacturers including Ford, GM, Stellantis, Tesla, Gillette, and Boston Scientific, today announced an enhancement to its Advanced Product Quality Planning (APQP) solution with QPS PRO—a centralized, fully digital system of record for APQP, Control Plans, PFMEA, DFMEA, and related quality processes that eliminates disconnected spreadsheets, paper files, and siloed systems.",
    "url": "https://finance.yahoo.com/news/datamyte-releases-qps-pro-meet-140300747.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "346ecf81-a165-3395-b6fd-ea0a113b7914",
      "content": {
        "id": "346ecf81-a165-3395-b6fd-ea0a113b7914",
        "contentType": "STORY",
        "title": "DATAMYTE RELEASES QPS PRO TO MEET AUTOMOTIVE OEM'S INCREASING DIGITAL QUALITY REQUIREMENTS",
        "description": "",
        "summary": "ASI DATAMYTE, Inc. (\"DATAMYTE\"), a leading digital transformation and quality management provider to global manufacturers including Ford, GM, Stellantis, Tesla, Gillette, and Boston Scientific, today announced an enhancement to its Advanced Product Quality Planning (APQP) solution with QPS PRO—a centralized, fully digital system of record for APQP, Control Plans, PFMEA, DFMEA, and related quality processes that eliminates disconnected spreadsheets, paper files, and siloed systems.",
        "pubDate": "2026-01-21T14:03:00Z",
        "displayTime": "2026-01-21T14:03:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/25db15fea17be2fd888fac78f3aa9499",
          "originalWidth": 400,
          "originalHeight": 100,
          "caption": "DATAMYTE corporate logo (PRNewsfoto/DATAMYTE)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xB8uQ4PPl2YxQr1Aftn1sA--~B/aD0xMDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/25db15fea17be2fd888fac78f3aa9499.cf.webp",
              "width": 400,
              "height": 100,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CtUDCLid4zq6O8EYY3kdAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/25db15fea17be2fd888fac78f3aa9499.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/datamyte-releases-qps-pro-meet-140300747.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/datamyte-releases-qps-pro-meet-140300747.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "F"
            },
            {
              "symbol": "GM"
            },
            {
              "symbol": "STLA"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "BSX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-21T13:55:48+00:00",
    "headline": "J&J's Guidance Wallops Views, But Boston Scientific, Medtronic Take A Toll",
    "summary": "Johnson & Johnson stock fell Wednesday despite a fourth-quarter beat as Medtronic and Boston Scientific continued gaining share in PFA.",
    "url": "https://www.investors.com/news/technology/johnson-and-johnson-stock-jnj-earnings-q4-2025/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "2a14968b-af49-395f-8455-489539a6620c",
      "content": {
        "id": "2a14968b-af49-395f-8455-489539a6620c",
        "contentType": "STORY",
        "title": "J&J's Guidance Wallops Views, But Boston Scientific, Medtronic Take A Toll",
        "description": "",
        "summary": "Johnson & Johnson stock fell Wednesday despite a fourth-quarter beat as Medtronic and Boston Scientific continued gaining share in PFA.",
        "pubDate": "2026-01-21T13:55:48Z",
        "displayTime": "2026-01-21T13:55:48Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/2a14968b-af49-395f-8455-489539a6620c/j-j-s-guidance-wallops-views-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/0ae2b2db37883f68ee2069be9bd594e4",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rwA2Kba4.xjpNvtEg7n9QQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/0ae2b2db37883f68ee2069be9bd594e4.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9I9e__rmE38egilIIeIqrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/0ae2b2db37883f68ee2069be9bd594e4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/johnson-and-johnson-stock-jnj-earnings-q4-2025/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BSX"
            },
            {
              "symbol": "MDT"
            },
            {
              "symbol": "^DJI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-21T13:01:00+00:00",
    "headline": "Here's Why You Should Hold Bio-Rad Stock in Your Portfolio Now",
    "summary": "BIO benefits from steady Clinical Diagnostics demand and international growth, but macro pressures and currency headwinds could cap near-term upside.",
    "url": "https://finance.yahoo.com/news/heres-why-hold-bio-rad-130100995.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "a45e3c47-db27-38dc-970b-be641d62f7e0",
      "content": {
        "id": "a45e3c47-db27-38dc-970b-be641d62f7e0",
        "contentType": "STORY",
        "title": "Here's Why You Should Hold Bio-Rad Stock in Your Portfolio Now",
        "description": "",
        "summary": "BIO benefits from steady Clinical Diagnostics demand and international growth, but macro pressures and currency headwinds could cap near-term upside.",
        "pubDate": "2026-01-21T13:01:00Z",
        "displayTime": "2026-01-21T13:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Z6CaNjdpI8OLeo5.Ul_eA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o6kyOwY40meLORq99yf8XA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-hold-bio-rad-130100995.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-hold-bio-rad-130100995.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIO"
            },
            {
              "symbol": "BIO-B"
            },
            {
              "symbol": "NVST"
            },
            {
              "symbol": "BSX"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-21T12:58:00+00:00",
    "headline": "Here's Why You Should Retain Revvity Stock in Your Portfolio for Now",
    "summary": "Revvity's diagnostics strength and fast-growing Signals Software support long-term growth, even as macro pressures and weak funding linger.",
    "url": "https://finance.yahoo.com/news/heres-why-retain-revvity-stock-125800699.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "cf79b557-1b48-3e1f-91da-c9a05b656b77",
      "content": {
        "id": "cf79b557-1b48-3e1f-91da-c9a05b656b77",
        "contentType": "STORY",
        "title": "Here's Why You Should Retain Revvity Stock in Your Portfolio for Now",
        "description": "",
        "summary": "Revvity's diagnostics strength and fast-growing Signals Software support long-term growth, even as macro pressures and weak funding linger.",
        "pubDate": "2026-01-21T12:58:00Z",
        "displayTime": "2026-01-21T12:58:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Z6CaNjdpI8OLeo5.Ul_eA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o6kyOwY40meLORq99yf8XA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-retain-revvity-stock-125800699.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-retain-revvity-stock-125800699.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RVTY"
            },
            {
              "symbol": "STE"
            },
            {
              "symbol": "BSX"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-21T12:54:00+00:00",
    "headline": "Is IDEXX Laboratories Stock the Right Pick for Your Portfolio Now?",
    "summary": "IDXX rides on strong CAG Diagnostics momentum and growing global software adoption, but currency pressure and solvency risks cloud the outlook.",
    "url": "https://finance.yahoo.com/news/idexx-laboratories-stock-pick-portfolio-125400239.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "20af8c27-18be-3b53-b239-70f23f9038a9",
      "content": {
        "id": "20af8c27-18be-3b53-b239-70f23f9038a9",
        "contentType": "STORY",
        "title": "Is IDEXX Laboratories Stock the Right Pick for Your Portfolio Now?",
        "description": "",
        "summary": "IDXX rides on strong CAG Diagnostics momentum and growing global software adoption, but currency pressure and solvency risks cloud the outlook.",
        "pubDate": "2026-01-21T12:54:00Z",
        "displayTime": "2026-01-21T12:54:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TNBAnrhWOnvvvNSvMEIuFg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rP7ZEHNft_Sb_FB9M.3i3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/idexx-laboratories-stock-pick-portfolio-125400239.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/idexx-laboratories-stock-pick-portfolio-125400239.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IDXX"
            },
            {
              "symbol": "BSX"
            },
            {
              "symbol": "NVST"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-21T15:49:00+00:00",
    "headline": "CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February",
    "summary": "CAPR said the FDA wants the full HOPE-3 study report for Deramiocel and confirmed no new clinical trials are needed.",
    "url": "https://finance.yahoo.com/news/capr-updates-fda-deramiocel-bla-154900055.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "f396ab58-8ebb-3737-848a-d6e2691d9e0b",
      "content": {
        "id": "f396ab58-8ebb-3737-848a-d6e2691d9e0b",
        "contentType": "STORY",
        "title": "CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February",
        "description": "",
        "summary": "CAPR said the FDA wants the full HOPE-3 study report for Deramiocel and confirmed no new clinical trials are needed.",
        "pubDate": "2026-01-21T15:49:00Z",
        "displayTime": "2026-01-21T15:49:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rR6iZHXu8FRY2qc4ebuBNA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TXlDKOevAW4cJAnlMECSwQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/capr-updates-fda-deramiocel-bla-154900055.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/capr-updates-fda-deramiocel-bla-154900055.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "STE"
            },
            {
              "symbol": "BSX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]